Conz. SRI, FOCIS or SAR haven't released the presentation and I doubt they will. What I do expect is for more details from this study to appear in some scientific journals over the coming weeks or months.
All we know is that TYK2 "significantly reduces inflammation and disease severity" from the RNS. How significantly and how many mice showed these results (maybe 10 out of 10 again) should become apparent when this is published..
I do hope time gets the nobel prize . if he does the share price will have moved up to where it should be . people should realise the time it takes for pharms to get to market before investing . high risk high gaines or losses . sars pipeline is very good . Rns is good news.
for once in my investing life I bought shares the day before an rns. then I saw the rise this morning and got all excited. despite all of that the sp drops. still, there's time for people to see the light of day over the next week or so and reward my foresight/good fortune with big buys of their own GLA
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.